Patients with Crohn's disease who lose some or all of their initial therapeutic response to infliximab can benefit from dose intensification. Regueiro et al. retrospectively analyzed 293 patients ...

According to a 2022 study from the United Kingdom, IBD specialists were more likely to choose vedolizumab over infliximab for people with Crohn’s disease who also had congestive heart failure ...

Patients with Crohn's disease are faced with a lifetime of ... became steroid-dependant or steroid-refractory, followed by infliximab if immunosuppression failed to control the symptoms.

Crohn’s disease involves inflammation of the gastrointestinal ... Biologic therapies such as infliximab and adalimumab are other possible treatments for Crohn’s. Your doctor may also prescribe ...

(2020). Rapid weight gain in infliximab treated Crohn's disease patients is sustained over time: Real-life data over 12 months. https://pubmed.ncbi.nlm.nih.gov/33108226/ Learn about interactions ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

In the US Renflexis (infliximab-abda) is approved in adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis ...